8month
months of reported misuse cases
Anthropic reported that it has disrupted multiple attempts to use its AI models, including Claude, for research related to biological weapons development over the past eight months.
10 Sep (reported 11 Sep)
Every figure reported in biotechnology news this week, with what each figure measures, when it was reported and where it was published.
83 figures were reported across 45 biotechnology articles in this window. The table lists the 60 carried by the highest-ranked articles.
Anthropic reported that it has disrupted multiple attempts to use its AI models, including Claude, for research related to biological weapons development over the past eight months.
10 Sep (reported 11 Sep)
The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.
11 Sep
The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.
11 Sep
The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.
11 Sep
The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Moderna and Merck & Co. announced that their mRNA cancer vaccine successfully extended patient survival in a phase 3 clinical study.
11 Sep
Anthropic reported on September 10, 2026, that it disrupted several attempts by researchers to use its Claude AI models for biological research potentially linked to biological weapons development.
10 Sep
Anthropic reported on September 10, 2026, that it disrupted several attempts by researchers to use its Claude AI models for biological research potentially linked to biological weapons development.
10 Sep
On September 7, 2026, the U.S. Department of Health and Human Services (HHS) announced four permanent senior leadership appointments at the FDA.
07 Sep (reported 09 Sep)
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
The National Commission into the Regulation of AI in Healthcare, led by Professors Alastair Denniston and Henrietta Hughes, published its recommendations on 10 September 2026 to improve AI regulation in the UK.
09 Sep — due 10 Sep 2026
On September 8, 2026, Google DeepMind launched AlphaGenome Atlas, a platform containing predictions for the molecular effects of 9 billion single-nucleotide variants in the human genome.
08 Sep
On September 8, 2026, Google DeepMind launched AlphaGenome Atlas, a platform containing predictions for the molecular effects of 9 billion single-nucleotide variants in the human genome.
08 Sep
Novartis announced that the phase 3 Harbor trial for its drug candidate del-desiran failed to meet its primary endpoint.
08 Sep
Cleveland Clinic, RIKEN, and IBM have been named finalists for the 2026 ACM Gordon Bell Prize for their quantum-HPC chemistry research.
09 Sep
Cleveland Clinic, RIKEN, and IBM have been named finalists for the 2026 ACM Gordon Bell Prize for their quantum-HPC chemistry research.
09 Sep
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
08 Sep
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
08 Sep
GE HealthCare is reportedly in advanced talks to acquire the radiopharmaceutical developer Sofie Biosciences.
13 Sep
GSK and Hansoh Pharma reported that their antibody-drug conjugate, risvutatug rezetecan, achieved a median overall survival of 18.5 months in a phase 3 lung cancer trial.
12 Sep
Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.
12 Sep
Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.
12 Sep
Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.
12 Sep
Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.
12 Sep
Multifamily developer LCOR acquired a life sciences development site at 309 East 94th Street in Manhattan's Upper East Side from Taconic Partners for $73 million.
10 Sep (reported 11 Sep)
Multifamily developer LCOR acquired a life sciences development site at 309 East 94th Street in Manhattan's Upper East Side from Taconic Partners for $73 million.
10 Sep (reported 11 Sep)
Multifamily developer LCOR acquired a life sciences development site at 309 East 94th Street in Manhattan's Upper East Side from Taconic Partners for $73 million.
10 Sep (reported 11 Sep)
Nutromics received FDA breakthrough device designation in the U.S. during the week of September 11, 2026, for its wearable patch designed to monitor vancomycin levels in real time.
11 Sep
Nutromics received FDA breakthrough device designation in the U.S. during the week of September 11, 2026, for its wearable patch designed to monitor vancomycin levels in real time.
11 Sep
Nutromics received FDA breakthrough device designation in the U.S. during the week of September 11, 2026, for its wearable patch designed to monitor vancomycin levels in real time.
11 Sep
Nutromics received FDA breakthrough device designation in the U.S. during the week of September 11, 2026, for its wearable patch designed to monitor vancomycin levels in real time.
11 Sep
Researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London published a study in Nature Genetics on September 11, 2026, regarding the impact of cancer treatments on healthy tissue.
11 Sep
Bebop is expanding its dairy-free, plant-fat ice cream brand from Taiwan into the broader APAC market.
11 Sep
Andy Plump, the President of Research and Development at Takeda, will depart from the company in June 2027.
11 Sep
Frazier Life Sciences has successfully raised over $1.1 billion for its public fund dedicated to small and midsize biotech companies.
10 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
Tyra Biosciences reported initial phase 2 clinical trial data for its drug candidate dabogratinib in treating bladder cancer.
09 Sep
Tyra Biosciences reported initial phase 2 clinical trial data for its drug candidate dabogratinib in treating bladder cancer.
09 Sep
Luma Group announced the final close of its inaugural venture capital fund dedicated to life sciences.
09 Sep
Luma Group announced the final close of its inaugural venture capital fund dedicated to life sciences.
09 Sep
Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.
08 Sep (reported 09 Sep)
Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.
08 Sep (reported 09 Sep)
Solstice Oncology has raised $225 million in a series A funding round.
09 Sep
Schrödinger has launched a new biotechnology company named Tectora Therapeutics, which will focus on immunology and inflammation research.
09 Sep
On September 9, 2026, a U.K. commission released 44 recommendations for regulating artificial intelligence in medicine.
03 Sep (reported 09 Sep)
The US Food and Drug Administration (FDA) announced that priority review voucher fees will decrease for the 2027 fiscal year.
09 Sep
On September 9, 2026, the US FDA granted accelerated approval to AstraZeneca's drug Etcamah.
09 Sep
Irish startup LEP Biomedical is developing a dissolvable implant designed to release glaucoma medication over two years to improve post-surgical recovery.
08 Sep
Irish startup LEP Biomedical is developing a dissolvable implant designed to release glaucoma medication over two years to improve post-surgical recovery.
08 Sep
Irish startup LEP Biomedical is developing a dissolvable implant designed to release glaucoma medication over two years to improve post-surgical recovery.
08 Sep
BrainChild, a startup spun out of Seattle Children’s Hospital, has raised $116 million in funding.
08 Sep
MIT Technology Review published its annual '35 Innovators Under 35' list for 2026, featuring individuals selected from 550 nominations across fields like AI and biotechnology.
08 Sep
60 of 83 figures are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
Publishers cited most often across the events on this page.
Choose the topics and sources that matter to you. Dailyn turns them into one concise digest.
Build my digest →Dailyn’s analysis engine screens the week’s reporting for relevance, deduplicates overlapping coverage into distinct dated events, and ranks those events by significance, source corroboration and recency. The highest-ranked events form the core of the weekly briefing.
Every line is a fact taken verbatim from a single dated article, and that article is linked in the same row. Nothing on the page is written or inferred beyond the article set.
The analysis engine extracts facts, entities and figures from the week’s reporting, and the editorial synthesis is generated from that event data. Published claims remain traceable to the underlying reporting.
A new briefing is issued for every ISO week, and the key-numbers section is refreshed with it. Each page states the exact window of dates it covers.
Dailyn’s analysis engine processes everything its monitored sources published this week: it deduplicates overlapping coverage, clusters reporting into distinct dated events, extracts the companies, deals and figures involved, and ranks the results by significance, corroboration and recency.
Everything Dailyn’s monitored sources published across the seven-day window.
The engine filters out off-topic and low-quality reporting.
Articles the engine tagged with this industry inside the window.
Sector articles that reported at least one figure inside the window.
The figures this page prints, each quoted exactly as its article reported it.
Events ranked by significance, corroboration and recency.
Every line on this page is a fact taken verbatim from a single dated article, with that article linked in the same row. Nothing on this page is written or inferred beyond the article set.
Duplicate reports of the same event are collapsed to one entry; the corroborating-source count says how many outlets carried it.
Dates are publication dates. Where an article states a different date for the event itself, that date is shown first and the publication date in brackets. A date the article gives for something still to come is shown as "due".
A figure is listed exactly as the article reported it. Figures are not converted, rebased, summed or compared across articles.
Every event stays linked to the reporting it was built from.
Pick the topics and sources that matter to you. Dailyn reads them every day and sends one concise digest.